Apr 246 - Cancer Science

Relevant Publications

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy.

Issue Release: 2024

Do cash or digital payment modalities affect community health worker performance? - a case study of a remote refugee settlement in Western Uganda.

Issue Release: 2024

Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.

Issue Release: 2023

TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.

Issue Release: 2023

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells.

Issue Release: 2023

APR-246 enhances colorectal cancer sensitivity to radiotherapy.

Issue Release: 2023

Fertility awareness and teenage pregnancy in rural western Uganda: a community-based cross-sectional study.

Issue Release: 2023

APR-246 increases tumor antigenicity independent of p53.

Issue Release: 2023

PRIMA-1/APR-246 can partially rescue in vitro cell adhesion of patient-derived junctional epidermolysis bullosa epidermal cells.

Issue Release: 2023

The Impact of TP53 Mutations and Use of the TP53-Mutation-Reactivating Agent APR-246 on Metastatic Castrate-Sensitive Prostate Cancer.

Issue Release: 2023

Targeting mutant-p53 for cancer treatment: Are we there yet?

Issue Release: 2023

Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.

Issue Release: 2023

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.

Issue Release: 2023

Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.

Issue Release: 2022

APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells.

Issue Release: 2022

Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for -Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Issue Release: 2022

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.

Issue Release: 2022

Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.

Issue Release: 2022

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.

Issue Release: 2022

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Issue Release: 2022

How Does an MDT Work?

What Nutritional Resources are Available?

What is MRI in Cancer Diagnosis?

How Does Cancer Invasion Occur?

How Do OTs Manage Cancer-Related Fatigue?

What Types of Items are Commonly Auctioned?

How Does Remote Monitoring Benefit Cancer Patients?

What is an Appeals Council Review?

What Factors Influence BBB Permeability in Cancer?

Are There Alternatives to EtO Sterilization?

Partnered Content Networks

Relevant Topics